---
title: "IBDex frozen atlas converts bulk transcriptomics into reusable IBD reference"
id: "medrxiv-17-ibdex-a-frozen-patient-scale-atlas-for-bulk-transcriptomics-in-inflammatory"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-ibdex-a-frozen-patient-scale-atlas-for-bulk-transcriptomics-in-inflammatory"
content_type: "clinical_feed_article"
specialty: "Gastroenterology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.20.26365993v1?rss=1"
published_at: "2026-10-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# IBDex frozen atlas converts bulk transcriptomics into reusable IBD reference
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-ibdex-a-frozen-patient-scale-atlas-for-bulk-transcriptomics-in-inflammatory
- **Specialty:** [Gastroenterology](https://medichelpline.com/clinical-feed/gastroenterology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.20.26365993v1?rss=1)
- **Published At:** 2026-10-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators assembled **IBDex** from 3,168 intestinal biopsies taken from 1,680 patients spanning Crohn’s disease, ulcerative colitis and non-IBD controls; data originated from four cohorts and public repositories. - The team trained a tissue-aware conditional variational autoencoder on a 3,000-gene interface, with adversarial suppression of cohort identity; the model’s scaling, encoder, decoder, pathway basis and phenotype directions were frozen for reuse. - Phenotype-anchored counterfactual perturbation (**PACP**) generated anatomy-conditioned gene-response maps that separate inflammation-related signals from disease-state signals. - In held-out data, dataset identity classification dropped near chance (balanced accuracy 0.307 vs 0.250), while anatomy, diagnosis and inflammation remained recoverable (inflammation AUC 0.82), showing successful cohort harmonization without retraining. - Marginal differential expression conflated inflammation and disease state (rho = 0.834); transferred PACP maps reversed that relationship (rho = -0.161), attributing inflammation to **TNF-NF-kappaB** programs and disease state to proliferative, type I interferon and metabolic programs. - Among 93 patients in combined endoscopic and histological remission, inflammation signatures approached control levels (AUC 0.58) but molecular disease state persisted (AUC 0.725; P = 1.8 x 10^-10). - The frozen atlas recovered clinical, single-cell-defined and disease-behavior structure in unseen cohorts without parameter updates, tracked responder trajectories in an olamkicept trial, and discriminated PSC (patient-level AUC 0.794) and CRC (AUC 0.938–1.000). - Where de novo differential expression failed, transferred response maps remained reproducible (rho ≥ 0.89). - All construction cohorts and reference outputs are publicly available; the authors distributed reference coordinates, pathway scores, axis scores and per-gene standardization as part of the released package.
## Clinical Analysis & Structured Key Points
IBDex: A Frozen Patient-Scale Atlas for Bulk Transcriptomics in Inflammatory Bowel Disease | medRxiv Skip to main content IBDex: A Frozen Patient-Scale Atlas for Bulk Transcriptomics in Inflammatory Bowel Disease View ORCID Profile Ajith Kumar Madeswaran , View ORCID Profile Animesh Acharjee doi: https://doi.org/10.64898/2026.10.20.26365993 Ajith Kumar Madeswaran University of Birmingham Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ajith Kumar Madeswaran Animesh Acharjee University of Birmingham Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Animesh Acharjee For correspondence: a.acharjee{at}bham.ac.uk Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background and Aims: Bulk mucosal RNA sequencing in inflammatory bowel disease (IBD) is analyzed one cohort at a time, so each study rebuilds its own molecular scale. We aimed to build a frozen atlas that new cohorts could use without retraining. Methods: We built IBDex from 3,168 intestinal biopsies from 1,680 patients with Crohn's disease, ulcerative colitis or no IBD, drawn from four cohorts. Patients were kept within a single training, validation or test partition. A tissue-aware conditional variational autoencoder with adversarial suppression of cohort identity was trained on a 3,000-gene interface. The scaling, encoder, decoder, pathway basis and phenotype directions were then frozen. Phenotype-anchored counterfactual perturbation (PACP) produced anatomy-conditioned gene-response maps. We tested the atlas without parameter updates in three unseen IBD cohorts, a longitudinal olamkicept trial, and cohorts with primary sclerosing cholangitis (PSC) or colorectal cancer (CRC). Results: In held-out data, dataset identity fell to near chance (balanced accuracy 0.307 vs 0.250). Anatomy, diagnosis and inflammation remained recoverable (inflammation AUC 0.82). Marginal differential expression conflated inflammation and disease state (rho = 0.834). PACP separated them (rho = -0.161), with inflammation driven by TNF-NF-kappaB, and disease state by proliferative, type I interferon and metabolic programs. In 93 patients in combined endoscopic and histological remission, inflammation approached controls (AUC 0.58), but disease state stayed displaced (AUC 0.725, P = 1.8 x 10^-10). The frozen atlas recovered clinical, single-cell-defined and disease-behavior structure in unseen cohorts. It also tracked responder trajectories during olamkicept therapy and separated PSC (patient-level AUC 0.794) and CRC (AUC 0.938-1.000). Where de novo differential expression became unreliable, transferred response maps stayed reproducible (rho >= 0.89). Conclusions: IBDex turns historical bulk biopsy data into a reusable reference. It shows that deep remission moves inflammation toward control levels but leaves a persistent molecular disease state. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All construction cohorts are public. GSE193677, GSE165512, GSE130038, GSE235236, GSE66207, GSE50760 and GSE171770 are available from the Gene Expression Omnibus, E-MTAB-9658 from ArrayExpress, iHMP2 from the Inflammatory Bowel Disease Multi'omics Database, IBDome from its project portal and TCGA-COAD from the Genomic Data Commons. Reference coordinates, pathway scores and axis scores for all 3,168 construction biopsies, together with the frozen panel membership and the per-gene standardization and clipping statistics, are distributed with the released package. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All construction cohorts are public. GSE193677, GSE165512, GSE130038, GSE235236, GSE66207, GSE50760 and GSE171770 are available from the Gene Expression Omnibus, E-MTAB-9658 from ArrayExpress, iHMP2 from the Inflammatory Bowel Disease Multi'omics Database, IBDome from its project portal and TCGA-COAD from the Genomic Data Commons. Reference coordinates, pathway scores and axis scores for all 3,168 construction biopsies, together with the frozen panel membership and the per-gene standardization and clipping statistics, are distributed with the released package. https://ibdexmd.org Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Back to top Previous Next Posted October 22, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following IBDex: A Frozen Patient-Scale Atlas for Bulk Transcriptomics in Inflammatory Bowel Disease Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share IBDex: A Frozen Patient-Scale Atlas for Bulk Transcriptomics in Inflammatory Bowel Disease Ajith Kumar Madeswaran , Animesh Acharjee medRxiv 2026.10.20.26365993; doi: https://doi.org/10.64898/2026.10.20.26365993 Share This Article: Copy Citation Tools IBDex: A Frozen Patient-Scale Atlas for Bulk Transcriptomics in Inflammatory Bowel Disease Ajith Kumar Madeswaran , Animesh Acharjee medRxiv 2026.10.20.26365993; doi: https://doi.org/10.64898/2026.10.20.26365993 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (633) Allergy and Immunology (914) Anesthesia (344) Cardiovascular Medicine (4940) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (670) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1665) Epidemiology (16153) Forensic Medicine (35) Gastroenterology (1235) Genetic and Genomic Medicine (7205) Geriatric Medicine (747) Health Economics (1088) Health Informatics (5220) Health Policy (1454) Health Systems and Quality Improvement (1812) Hematology (597) HIV/AIDS (1370) Infectious Diseases (except HIV/AIDS) (16422) Intensive Care and Critical Care Medicine (1192) Medical Education (690) Medical Ethics (156) Nephrology (739) Neurology (7493) Nursing (375) Nutrition (1114) Obstetrics and Gynecology (1280) Occupational and Environmental Health (1028) Oncology (3708) Ophthalmology (1079) Orthopedics (401) Otolaryngology (462) Pain Medicine (491) Palliative Medicine (142) Pathology (716) Pediatrics (1844) Pharmacology and Therapeutics (748) Primary Care Research (781) Psychiatry and Clinical Psychology (6063) Public and Global Health (9911) Radiology and Imaging (2498) Rehabilitation Medicine and Physical Therapy (1499) Respiratory Medicine (1263) Rheumatology (655) Sexual and Reproductive Health (794) Sports Medicine (593) Surgery (794) Toxicology (109) Transplantation (315) Urology (302)
## Related Clinical Research

- [Housing-Based SES (HOUSES) and Geospatial Targeting to Improve Colorectal Cancer Screening in Rura](https://medichelpline.com/clinical-feed/medrxiv-9-from-housing-to-hotspots-integrating-a-housing-based-measure-of-individual.md)
- [Metformin, antibiotics, painkillers, and PPIs alter the gut microbiome and affect colorectal neopl](https://medichelpline.com/clinical-feed/medrxiv-10-metformin-antibiotics-painkillers-and-proton-pump-inhibitors-shape-the-gut.md)
- [Beyond conventional biomarkers: editorial on novel biomarkers and combinatorial approaches for imm](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-editorial-beyond-conventional-biomarkers-unlocking-immunotherapy-response.md)
- [Could we one day vaccinate against every cancer? Latest on cancer vaccine trials and implications](https://medichelpline.com/clinical-feed/stat-news-3-could-we-one-day-vaccinate-against-every-cancer.md)
- [Structured aerobic exercise linked to lower cancer recurrence and improved survival](https://medichelpline.com/clinical-feed/medical-news-today-0-aerobic-exercise-could-help-improve-outlook-after-cancer-treatment.md)

## Navigation
- [← Back to Gastroenterology Feed](https://medichelpline.com/clinical-feed/gastroenterology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.